Pfizer predicts vaccine sales will accrue USD 26 billion by end of 2021
Category: #business |   By Pankaj Singh |   Date: 2021-05-06

Pfizer predicts vaccine sales will accrue USD 26 billion by end of 2021

Pfizer Inc., the American multinational pharmaceutical company has reportedly raised the annual sales forecast for its COVID-19 vaccine by 70% and expects to accrue revenues worth USD 26 billion by the end of 2021.

The announcement comes amidst the surging demand for Pfizer’s successful COVID-19 vaccine from governments across the globe. The pharmaceutical company has signed several contracts with numerous countries to deliver over 1.6 billion vaccine doses in 2021 alone, sources claimed.

In this context, Chief Executive Officer of Pfizer Albert Bourla confirmed the news claiming that the demand for the company’s COVID-19 vaccines is expected to rise in the next few years.

According to reliable sources, Pfizer is likely to apply for full approval of its vaccines in the United States for people over the age of 16. The drug company is also seeking a EUA for children aged between 12 to 15 years in the U.S.

Pfizer has been researching the efficacy and safety of its vaccines for children between 2-11 years and intends to offer vaccines to children by September this year, cited sources with relevant information.

Notably, Pfizer Inc. and BioNTech SE have joined hands to develop this vaccine, with all profits and revenue being shared equally. The duo intends to produce around 2.5 billion vaccine doses this year which if sold at current prices are likely to be 50% more than the estimations of approximately USD 26 billion.

Pfizer generated around USD 3.5 billion in terms of revenue during the first quarter of 2021 alone, surpassing analysts’ predictions of USD 3.28 billion.

Reportedly, Pfizer also intends to increase its R&D expenditure in order to improve the drug discovery processes using the messenger RNA technology for the COVID-19 vaccine. It is also developing two flu vaccines which are anticipated to enter clinical trials by September 2021.

Source Credits –

https://www.investing.com/news/stock-market-news/pfizer-lifts-annual-sales-forecast-for-covid19-vaccine-2494137

 

  • shareShare
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh     Twitter

Pankaj Singh

With a commendable experience of content creation under his belt, Pankaj Singh, a qualified Post Graduate in Management, boasts of having worked as a freelance writer and an insurance underwriter. Additionally, Pankaj has also enriched his qualification portfolio with Read more...

More News By Pankaj Singh

U.K.’s economy to slump worse than other countries in 2023, says IMF

U.K.’s economy to slump worse than other countries in 2023, says IMF

By Pankaj Singh

The U.K. economy is reportedly set to decline and perform worse as compared to other major nations, notably Russia, as the cost of living remains high, as per the International Monetary Fund (IMF). According to the IMF, the economic output would d...

Oil prices hike as China curbs travel rules and US fights winter storm

Oil prices hike as China curbs travel rules and US fights winter storm

By Pankaj Singh

Oil prices reportedly surged to record a three-week high as China lifted its zero-covid policy and extremely cold weather in the United States forced refinery closures along the critical Texas Gulf Coast. Brent crude rose 88 US cents, or 1.1%, to ...

EU accepts carbon market access for $21.3 billion in the energy shift

EU accepts carbon market access for $21.3 billion in the energy shift

By Pankaj Singh

The European Union (EU) policymakers have reportedly agreed to raise nearly $21.3 billion (€20 billion) from the carbon market of that region, to support financing the bloc's strategy to alleviate its reliance on Russia for natural gas in a ...